South Korea · Delayed Price · Currency is KRW Curexo Statistics
Total Valuation
Curexo has a market cap or net worth of KRW 604.02 billion. The enterprise value is 585.18 billion.
| Market Cap | 604.02B |
| Enterprise Value | 585.18B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Curexo has 41.09 million shares outstanding. The number of shares has increased by 0.20% in one year.
| Current Share Class | 41.09M |
| Shares Outstanding | 41.09M |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 6.52% |
| Float | 28.37M |
Valuation Ratios
The trailing PE ratio is 219.40.
| PE Ratio | 219.40 |
| Forward PE | n/a |
| PS Ratio | 8.10 |
| PB Ratio | 6.28 |
| P/TBV Ratio | 6.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 113.69, with an EV/FCF ratio of -42.58.
| EV / Earnings | 211.14 |
| EV / Sales | 7.85 |
| EV / EBITDA | 113.69 |
| EV / EBIT | 247.77 |
| EV / FCF | -42.58 |
Financial Position
The company has a current ratio of 20.69, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.69 |
| Quick Ratio | 10.94 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | -0.08 |
| Interest Coverage | 27.02 |
Financial Efficiency
Return on equity (ROE) is 2.92% and return on invested capital (ROIC) is 3.14%.
| Return on Equity (ROE) | 2.92% |
| Return on Assets (ROA) | 1.45% |
| Return on Invested Capital (ROIC) | 3.14% |
| Return on Capital Employed (ROCE) | 2.44% |
| Weighted Average Cost of Capital (WACC) | 11.53% |
| Revenue Per Employee | 2.57B |
| Profits Per Employee | 95.57M |
| Employee Count | 29 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.29 |
Taxes
In the past 12 months, Curexo has paid 59.32 million in taxes.
| Income Tax | 59.32M |
| Effective Tax Rate | 2.10% |
Stock Price Statistics
The stock price has increased by +106.75% in the last 52 weeks. The beta is 1.32, so Curexo's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +106.75% |
| 50-Day Moving Average | 16,672.40 |
| 200-Day Moving Average | 12,071.60 |
| Relative Strength Index (RSI) | 45.48 |
| Average Volume (20 Days) | 1,161,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Curexo had revenue of KRW 74.53 billion and earned 2.77 billion in profits. Earnings per share was 67.00.
| Revenue | 74.53B |
| Gross Profit | 24.82B |
| Operating Income | 2.36B |
| Pretax Income | 2.83B |
| Net Income | 2.77B |
| EBITDA | 5.15B |
| EBIT | 2.36B |
| Earnings Per Share (EPS) | 67.00 |
Balance Sheet
The company has 20.01 billion in cash and 1.17 billion in debt, with a net cash position of 18.84 billion or 458.51 per share.
| Cash & Cash Equivalents | 20.01B |
| Total Debt | 1.17B |
| Net Cash | 18.84B |
| Net Cash Per Share | 458.51 |
| Equity (Book Value) | 96.25B |
| Book Value Per Share | 2,342.39 |
| Working Capital | 82.92B |
Cash Flow
In the last 12 months, operating cash flow was -11.26 billion and capital expenditures -2.48 billion, giving a free cash flow of -13.74 billion.
| Operating Cash Flow | -11.26B |
| Capital Expenditures | -2.48B |
| Depreciation & Amortization | 2.79B |
| Net Borrowing | -666.29M |
| Free Cash Flow | -13.74B |
| FCF Per Share | -334.44 |
Margins
Gross margin is 33.31%, with operating and profit margins of 3.17% and 3.72%.
| Gross Margin | 33.31% |
| Operating Margin | 3.17% |
| Pretax Margin | 3.80% |
| Profit Margin | 3.72% |
| EBITDA Margin | 6.91% |
| EBIT Margin | 3.17% |
| FCF Margin | n/a |
Dividends & Yields
Curexo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.20% |
| Shareholder Yield | -0.20% |
| Earnings Yield | 0.46% |
| FCF Yield | -2.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 5, 2006. It was a forward split with a ratio of 2.
| Last Split Date | Apr 5, 2006 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Curexo has an Altman Z-Score of 47.96 and a Piotroski F-Score of 4.
| Altman Z-Score | 47.96 |
| Piotroski F-Score | 4 |